Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy.
Autoimmune blistering diseases
Cicatricial pemphigoid
Corticosteroids
Desmoglein-1
Desmoglein-3
Immunosuppressive drugs
Pemphigus vulgaris
Journal
Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
27
10
2018
accepted:
02
11
2018
pubmed:
11
2
2019
medline:
1
6
2019
entrez:
11
2
2019
Statut:
ppublish
Résumé
Pemphigus diseases (PDs) and mucous membrane pemphigoid (MMP) are a group of immune-mediated mucocutaneous disorders clinically characterized by the formation of blisters, erosions and ulcers. The skin and mucous membranes are predominantly affected, with the oropharyngeal mucosa as the initially involved site. Ocular involvement is also a frequent feature of these diseases. Because of the considerable overlap in their clinical presentations, the diagnosis of PDs vs. MMP can be challenging. A recognition of their specific immunological and histopathologic features is crucial in the differential diagnosis. Treatment modalities include systemically administered corticosteroids, steroid-sparing immunosuppressive agents, and biologic therapies (rituximab, intravenous immunoglobulins, and anti-tumor necrosis factor agents). Topical, oral, conjunctival, or intralesional corticosteroids as well as anti-inflammatory drugs and antibiotics are prescribed as needed.
Identifiants
pubmed: 30738958
pii: S1568-9972(19)30031-X
doi: 10.1016/j.autrev.2019.02.005
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Immunoglobulins, Intravenous
0
Immunosuppressive Agents
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
349-358Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.